olaparib

  • December 3, 2020 

    Olaparib Granted Positive EU Opinion for BRCA1/2+ Advanced Prostate CancerBookmark

    George Lundberg, MD

    A news story published by OncLive reports that the European Union’s Committee for Medicinal Products for Human Use recently approved the drug olaparib for treating patients with a subset of advanced castrate-resistant prostate cancers that have BRCA1/2 mutations.

    .

  • November 24, 2020 

    Two New Treatments Approved For Advanced Prostate CancerBookmark

    George Lundberg, MD

    A story published by the Prostate Cancer Foundation outlines two new treatment options approved by the U.S. Food and Drug Administration (FDA) this year. The two medications, rucaparib and olaparib, each target specific mutations that may be found in a patient’s tumor, and each was approved for a specific type of prostate cancer.

    .

  • May 30, 2020 

    Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian CancerBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    Clinical trial results have shown a 13-month overall survival benefit from maintenance therapy—treatment to prevent or delay recurrence—with olaparib for advanced ovarian cancer.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • April 9, 2020 

    FDA Approves Pancreatic Cancer Drug Treatment After It Was Shown to Increase Progression Free SurvivalBookmark

    George Lundberg, MD

    Article from Good News Network curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved the use of Lynparza (olaparib) for treating  stage 4 pancreatic cancer patients with hereditary BRCA mutation who have not progressed on platinum therapy. A clinical trial showed prolongation of progression free survival in this subset of patients.

    Go to full article published by Good News Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • January 31, 2020 

    FDA Grants Priority Review to Olaparib, Bevacizumab Combination for Ovarian CancerBookmark

    George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    In precision oncology, drugs combinations may provide new effective treatment.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • January 7, 2020 

    FDA Approves Lynparza as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic CancerBookmark

    George Lundberg, MD

    Article from The Cancer Letter curated by Editor in Chief George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved olaparib (Lynparza) for marketing and sales for a narrow group of metastatic pancreatic cancer patients, based on rates of progression-free survival in a clinical trial published in The New England Journal of Medicine.

    Go to full article published by The Cancer Letter.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.